Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 174

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism

Dai, Weiqi, Xu, Ling, Yu, Xiangnan, Zhang, Guangcong, Guo, Hongying, Liu, Hailin, Song, Guangqi, Weng, Shuqiang, Dong, Ling, Zhu, Jimin, Liu, Taotao, Guo, Chuanyong, Shen, Xizhong · 2020 · Journal of Hepatology

Abstract

BACKGROUND & AIMS Mitochondrial dysfunction and subsequent metabolic deregulation are commonly observed in cancers including hepatocellular carcinoma (HCC). When mitochondrial function is impaired, reductive glutamine metabolism is a major cellular carbon source for de novo lipogenesis to support cancer cell growth. The underlying regulators of reductively metabolized glutamine in mitochondrial dysfunction are not completely understood in tumorigenesis including in HCC. METHODS We systematically investigated the role of oxoglutarate dehydrogenase-like (OGDHL), one of the rate-limiting components of the key mitochondrial multi-enzyme OGDH complex (OGDHC), in the regulation of lipid metabolism in hepatoma cells and explored the underlying molecular mechanisms. RESULTS Lower expression of OGDHL was associated with advanced tumor stage, significantly worse survival and more frequent tumor recurrence in three independent cohorts totaling 681 postoperative HCC patients. Promoter hypermethylation and DNA copy deletion of OGDHL were independently correlated with reduced OGDHL expression in HCC specimens. Additionally, OGDHL overexpression significantly inhibited the growth of hepatoma cells as mouse xenografts while knockdown of OGDHL promoted proliferation in hepatoma cells. Mechanistically, OGDHL downregulation upregulated the α-ketoglutarate (αKG):citrate ratio by reducing OGDHC activity, which subsequently drove reductive carboxylation (RC) of glutamine-derived αKG for lipogenesis via retrograde TCA cycling in hepatoma cells. Notably, silencing of OGDHL activated the mTORC1 signaling pathway in an α-KG-dependent manner, which in turn transcriptionally induced expression of SCD1 and FASN, thus, enhancing de novo lipogenesis. Meanwhile, metabolic reprogramming in OGDHL-negative hepatoma cells provided an abundant supply of NADPH and GSH to support the cellular antioxidant system. The reduction of reductive glutamine metabolism through OGDHL overexpression or through use of glutaminase inhibitors sensitized tumor cells to sorafenib, a molecular-targeted therapy for HCC. CONCLUSION Our findings established that silencing of OGDHL contributed to HCC development and survival by regulating glutamine metabolic pathways, and suggest OGDHL as a promising prognostic biomarker and therapeutic target for HCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2019.12.015

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 174

Metadata

Authors
Dai, W., Xu, L., Yu, X., Zhang, G., Guo, H., Liu, H., Song, G., Weng, S., Dong, L., Zhu, J., Liu, T., Guo, C., & Shen, X.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2020-05
Volume
72
Issue
5
Pages
909-923
ISSN
0168-8278 (ISSN-L)
OpenAlex
W2996842212
Cited by
174
References
16
FWCI
3.32
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism. https://app.cochat.ai/papers/10.1016/j.jhep.2019.12.015
The paper
Dai, W., Xu, L., Yu, X., Zhang, G., Guo, H., Liu, H., Song, G., Weng, S., Dong, L., Zhu, J., Liu, T., Guo, C., & Shen, X. (2020). OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2019.12.015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.